A 6-part First-in-human Study of LOU064 Consisting of a 4-part Randomized, Double-blind, Placebo-controlled SAD and MAD Study to Investigate the Safety and Tolerability in Healthy Volunteers, Subjects With Atopic Diathesis and Subjects With Atopic Dermatitis, an Open-label Food Effect Study and a Double-blind Formulation Effect Study in Healthy Volunteers
Latest Information Update: 06 Dec 2024
At a glance
- Drugs Remibrutinib (Primary)
- Indications Atopic dermatitis; Urticaria
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 16 Feb 2020 Status changed from recruiting to completed.
- 29 Oct 2019 Planned End Date changed from 24 Dec 2019 to 27 Mar 2020.
- 29 Oct 2019 Planned primary completion date changed from 23 Dec 2019 to 27 Mar 2020.